Concepts (253)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pterygium | 5 | 2014 | 5 | 1.490 |
Why?
|
| Exfoliation Syndrome | 7 | 2021 | 12 | 0.910 |
Why?
|
| Glaucoma, Open-Angle | 7 | 2019 | 15 | 0.780 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2019 | 198 | 0.680 |
Why?
|
| Drug Delivery Systems | 7 | 2014 | 252 | 0.640 |
Why?
|
| Amino Acid Oxidoreductases | 5 | 2019 | 9 | 0.610 |
Why?
|
| Ophthalmic Solutions | 5 | 2014 | 9 | 0.560 |
Why?
|
| Limbus Corneae | 2 | 2014 | 2 | 0.560 |
Why?
|
| Aged | 16 | 2021 | 1740 | 0.480 |
Why?
|
| Conjunctiva | 1 | 2014 | 2 | 0.450 |
Why?
|
| Middle Aged | 18 | 2021 | 3601 | 0.440 |
Why?
|
| Male | 25 | 2021 | 6754 | 0.430 |
Why?
|
| Humans | 35 | 2021 | 14537 | 0.410 |
Why?
|
| Female | 26 | 2021 | 9103 | 0.390 |
Why?
|
| Medicine, African Traditional | 1 | 2012 | 25 | 0.390 |
Why?
|
| Mutation | 4 | 2018 | 306 | 0.380 |
Why?
|
| Dry Eye Syndromes | 1 | 2011 | 1 | 0.360 |
Why?
|
| Heredity | 1 | 2011 | 6 | 0.360 |
Why?
|
| Nanotechnology | 1 | 2011 | 28 | 0.350 |
Why?
|
| Adult | 17 | 2018 | 5913 | 0.340 |
Why?
|
| Nanoparticles | 1 | 2011 | 104 | 0.330 |
Why?
|
| Eye Banks | 1 | 2009 | 1 | 0.330 |
Why?
|
| Corneal Transplantation | 1 | 2009 | 1 | 0.330 |
Why?
|
| Tissue and Organ Procurement | 1 | 2009 | 14 | 0.330 |
Why?
|
| Genome-Wide Association Study | 3 | 2019 | 106 | 0.310 |
Why?
|
| Eye | 5 | 2017 | 13 | 0.300 |
Why?
|
| Anterior Chamber | 2 | 2021 | 4 | 0.290 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2019 | 176 | 0.280 |
Why?
|
| Case-Control Studies | 7 | 2021 | 480 | 0.260 |
Why?
|
| South Africa | 18 | 2018 | 7596 | 0.260 |
Why?
|
| Drug Carriers | 4 | 2013 | 93 | 0.250 |
Why?
|
| Sclera | 1 | 2005 | 1 | 0.240 |
Why?
|
| Surgical Flaps | 1 | 2005 | 1 | 0.240 |
Why?
|
| Prosthesis Implantation | 1 | 2005 | 1 | 0.240 |
Why?
|
| Glaucoma Drainage Implants | 1 | 2005 | 1 | 0.240 |
Why?
|
| Endocrinology | 1 | 2005 | 1 | 0.240 |
Why?
|
| Mydriatics | 1 | 2005 | 1 | 0.240 |
Why?
|
| Fundus Oculi | 1 | 2005 | 3 | 0.240 |
Why?
|
| Vision Screening | 1 | 2005 | 3 | 0.240 |
Why?
|
| Tablets | 4 | 2013 | 39 | 0.240 |
Why?
|
| Diabetic Retinopathy | 1 | 2005 | 5 | 0.240 |
Why?
|
| Polymers | 4 | 2013 | 133 | 0.230 |
Why?
|
| Ganciclovir | 4 | 2012 | 12 | 0.220 |
Why?
|
| Prospective Studies | 4 | 2014 | 1160 | 0.220 |
Why?
|
| Indomethacin | 2 | 2013 | 17 | 0.210 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2013 | 39 | 0.210 |
Why?
|
| Eye Proteins | 2 | 2014 | 4 | 0.210 |
Why?
|
| Cytoskeletal Proteins | 2 | 2014 | 5 | 0.210 |
Why?
|
| Glycoproteins | 2 | 2014 | 10 | 0.210 |
Why?
|
| Polyglycolic Acid | 3 | 2012 | 16 | 0.200 |
Why?
|
| Lactic Acid | 3 | 2012 | 34 | 0.200 |
Why?
|
| Cytomegalovirus Retinitis | 1 | 2002 | 1 | 0.200 |
Why?
|
| Ciliary Body | 1 | 2002 | 1 | 0.200 |
Why?
|
| Uveal Neoplasms | 1 | 2002 | 1 | 0.200 |
Why?
|
| Leiomyoma | 1 | 2002 | 4 | 0.190 |
Why?
|
| Animals | 7 | 2015 | 1081 | 0.190 |
Why?
|
| Promoter Regions, Genetic | 2 | 2019 | 36 | 0.190 |
Why?
|
| Steroid Hydroxylases | 1 | 2021 | 2 | 0.180 |
Why?
|
| Eye Diseases | 2 | 2011 | 7 | 0.180 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2002 | 195 | 0.170 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2019 | 14 | 0.160 |
Why?
|
| Genetic Variation | 1 | 2021 | 175 | 0.160 |
Why?
|
| Tretinoin | 1 | 2019 | 8 | 0.160 |
Why?
|
| Signal Transduction | 1 | 2019 | 33 | 0.160 |
Why?
|
| Membrane Proteins | 1 | 2019 | 36 | 0.160 |
Why?
|
| Corneal Ulcer | 2 | 1990 | 2 | 0.160 |
Why?
|
| Administration, Topical | 4 | 2013 | 12 | 0.160 |
Why?
|
| Calcium Channels | 2 | 2017 | 6 | 0.160 |
Why?
|
| Antiviral Agents | 2 | 2010 | 111 | 0.150 |
Why?
|
| PAX6 Transcription Factor | 1 | 2018 | 1 | 0.150 |
Why?
|
| Coloboma | 1 | 2018 | 1 | 0.150 |
Why?
|
| Nystagmus, Pathologic | 1 | 2018 | 1 | 0.150 |
Why?
|
| Cataract | 1 | 2018 | 2 | 0.150 |
Why?
|
| Alleles | 3 | 2017 | 143 | 0.140 |
Why?
|
| Point Mutation | 1 | 2017 | 16 | 0.140 |
Why?
|
| Treatment Outcome | 2 | 2014 | 889 | 0.140 |
Why?
|
| Recurrence | 2 | 2014 | 29 | 0.140 |
Why?
|
| Mutation, Missense | 1 | 2017 | 65 | 0.140 |
Why?
|
| Aqueous Humor | 2 | 2007 | 5 | 0.140 |
Why?
|
| Logistic Models | 2 | 2021 | 254 | 0.140 |
Why?
|
| Corneal Dystrophies, Hereditary | 1 | 2016 | 1 | 0.130 |
Why?
|
| Sulfotransferases | 1 | 2016 | 1 | 0.130 |
Why?
|
| Aged, 80 and over | 4 | 2021 | 468 | 0.130 |
Why?
|
| RNA, Long Noncoding | 1 | 2015 | 3 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2015 | 2 | 0.120 |
Why?
|
| Genetic Diseases, Inborn | 1 | 2015 | 4 | 0.120 |
Why?
|
| Genetic Loci | 1 | 2015 | 11 | 0.120 |
Why?
|
| Timolol | 1 | 2014 | 3 | 0.110 |
Why?
|
| Visual Acuity | 1 | 2014 | 4 | 0.110 |
Why?
|
| Postoperative Complications | 1 | 2014 | 34 | 0.110 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 64 | 0.110 |
Why?
|
| Conjunctivitis | 1 | 2013 | 1 | 0.110 |
Why?
|
| Eye, Artificial | 1 | 2013 | 3 | 0.110 |
Why?
|
| Anterior Eye Segment | 1 | 2013 | 3 | 0.110 |
Why?
|
| Ciprofloxacin | 1 | 2013 | 11 | 0.110 |
Why?
|
| Epithelial Cells | 1 | 2013 | 14 | 0.110 |
Why?
|
| Polyesters | 1 | 2013 | 16 | 0.110 |
Why?
|
| Chitosan | 1 | 2013 | 46 | 0.100 |
Why?
|
| Rabbits | 4 | 2014 | 35 | 0.100 |
Why?
|
| Follow-Up Studies | 1 | 2014 | 370 | 0.100 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 22 | 0.100 |
Why?
|
| Pedigree | 3 | 2018 | 30 | 0.100 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 45 | 0.100 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 411 | 0.100 |
Why?
|
| Interviews as Topic | 1 | 2012 | 203 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 293 | 0.090 |
Why?
|
| Adhesiveness | 1 | 2011 | 18 | 0.090 |
Why?
|
| Intraocular Pressure | 2 | 2014 | 4 | 0.090 |
Why?
|
| Posterior Eye Segment | 1 | 2010 | 4 | 0.090 |
Why?
|
| Young Adult | 3 | 2014 | 2498 | 0.090 |
Why?
|
| Drug Design | 1 | 2011 | 29 | 0.090 |
Why?
|
| Dexamethasone | 1 | 1990 | 13 | 0.090 |
Why?
|
| Polymorphism, Genetic | 1 | 2011 | 99 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 2 | 2021 | 17 | 0.090 |
Why?
|
| Vitreous Body | 1 | 2010 | 2 | 0.090 |
Why?
|
| Infusion Pumps, Implantable | 1 | 2010 | 2 | 0.090 |
Why?
|
| RNA, Messenger | 2 | 2021 | 32 | 0.080 |
Why?
|
| Time Factors | 1 | 2011 | 507 | 0.080 |
Why?
|
| Rural Population | 2 | 2012 | 654 | 0.080 |
Why?
|
| Polyglactin 910 | 1 | 2007 | 2 | 0.070 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 48 | 0.070 |
Why?
|
| Immunohistochemistry | 2 | 2019 | 26 | 0.070 |
Why?
|
| Gene Expression | 2 | 2018 | 43 | 0.070 |
Why?
|
| Phenotype | 2 | 2018 | 158 | 0.070 |
Why?
|
| Risk Factors | 2 | 2019 | 1475 | 0.060 |
Why?
|
| Solubility | 3 | 2014 | 51 | 0.060 |
Why?
|
| Ophthalmology | 1 | 2005 | 3 | 0.060 |
Why?
|
| Photography | 1 | 2005 | 5 | 0.060 |
Why?
|
| Safety | 1 | 2005 | 34 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2005 | 57 | 0.060 |
Why?
|
| Age Distribution | 1 | 2005 | 107 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2005 | 179 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 385 | 0.050 |
Why?
|
| Inflammation | 2 | 2013 | 104 | 0.050 |
Why?
|
| Child | 5 | 2018 | 2242 | 0.050 |
Why?
|
| Trachoma | 1 | 1982 | 1 | 0.050 |
Why?
|
| Blindness | 1 | 1982 | 2 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2014 | 260 | 0.050 |
Why?
|
| Retrospective Studies | 1 | 2005 | 799 | 0.050 |
Why?
|
| Conjunctivitis, Allergic | 1 | 2001 | 1 | 0.050 |
Why?
|
| Histamine H1 Antagonists | 1 | 2001 | 1 | 0.050 |
Why?
|
| Piperidines | 1 | 2001 | 4 | 0.050 |
Why?
|
| Anti-Retroviral Agents | 1 | 2006 | 551 | 0.050 |
Why?
|
| Benzimidazoles | 1 | 2001 | 13 | 0.050 |
Why?
|
| Delayed-Action Preparations | 2 | 2012 | 68 | 0.050 |
Why?
|
| Whole Exome Sequencing | 1 | 2021 | 3 | 0.050 |
Why?
|
| Poliomyelitis | 1 | 1981 | 5 | 0.050 |
Why?
|
| Prevalence | 1 | 2005 | 1192 | 0.040 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2021 | 25 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 2014 | 54 | 0.040 |
Why?
|
| Mass Screening | 1 | 2002 | 245 | 0.040 |
Why?
|
| Drug Compounding | 2 | 2012 | 22 | 0.040 |
Why?
|
| Kinetics | 2 | 2012 | 65 | 0.040 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 656 | 0.040 |
Why?
|
| Amyloid beta-Peptides | 1 | 2019 | 22 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2019 | 40 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2019 | 79 | 0.040 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2010 | 63 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 181 | 0.040 |
Why?
|
| Family | 1 | 2018 | 35 | 0.040 |
Why?
|
| Whole Genome Sequencing | 1 | 2018 | 44 | 0.040 |
Why?
|
| Genotype | 1 | 2019 | 442 | 0.040 |
Why?
|
| Molecular Chaperones | 1 | 2017 | 3 | 0.040 |
Why?
|
| Spheroids, Cellular | 1 | 2017 | 3 | 0.040 |
Why?
|
| Cell Adhesion | 1 | 2017 | 18 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 35 | 0.030 |
Why?
|
| Extracellular Matrix | 1 | 2017 | 13 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2017 | 41 | 0.030 |
Why?
|
| Foscarnet | 2 | 2007 | 4 | 0.030 |
Why?
|
| Viscosity | 2 | 2007 | 16 | 0.030 |
Why?
|
| Drug Implants | 2 | 2007 | 24 | 0.030 |
Why?
|
| Cornea | 1 | 2016 | 2 | 0.030 |
Why?
|
| Haplotypes | 1 | 2017 | 125 | 0.030 |
Why?
|
| Homozygote | 1 | 2016 | 61 | 0.030 |
Why?
|
| African Americans | 3 | 1987 | 47 | 0.030 |
Why?
|
| Oxidative Stress | 1 | 2015 | 19 | 0.030 |
Why?
|
| Japan | 1 | 2015 | 7 | 0.030 |
Why?
|
| MCF-7 Cells | 1 | 2015 | 6 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 20 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2015 | 12 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2015 | 15 | 0.030 |
Why?
|
| Chromosome Mapping | 1 | 2015 | 20 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2015 | 122 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 39 | 0.030 |
Why?
|
| Gonioscopy | 1 | 2014 | 2 | 0.030 |
Why?
|
| Visual Fields | 1 | 2014 | 2 | 0.030 |
Why?
|
| Mice | 1 | 2015 | 135 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2014 | 38 | 0.030 |
Why?
|
| Child, Preschool | 5 | 2001 | 1748 | 0.030 |
Why?
|
| Chorioallantoic Membrane | 1 | 2014 | 3 | 0.030 |
Why?
|
| Administration, Ophthalmic | 1 | 2014 | 3 | 0.030 |
Why?
|
| Chick Embryo | 1 | 2014 | 8 | 0.030 |
Why?
|
| Permeability | 1 | 2014 | 17 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2013 | 7 | 0.030 |
Why?
|
| Caco-2 Cells | 1 | 2013 | 10 | 0.030 |
Why?
|
| NF-kappa B | 1 | 2013 | 16 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2013 | 56 | 0.030 |
Why?
|
| Phospholipids | 1 | 2013 | 13 | 0.030 |
Why?
|
| Liposomes | 1 | 2013 | 33 | 0.030 |
Why?
|
| Antibody Formation | 1 | 2013 | 61 | 0.030 |
Why?
|
| Models, Molecular | 1 | 2013 | 84 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2013 | 45 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2012 | 2 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2012 | 3 | 0.030 |
Why?
|
| Introns | 1 | 2012 | 13 | 0.030 |
Why?
|
| Exons | 1 | 2012 | 17 | 0.030 |
Why?
|
| Nanostructures | 1 | 2013 | 40 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2013 | 107 | 0.030 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 90 | 0.020 |
Why?
|
| Sterilization | 1 | 2012 | 2 | 0.020 |
Why?
|
| Lens Implantation, Intraocular | 1 | 2012 | 2 | 0.020 |
Why?
|
| Crystallization | 1 | 2012 | 8 | 0.020 |
Why?
|
| Tensile Strength | 1 | 2012 | 13 | 0.020 |
Why?
|
| Drug Stability | 1 | 2012 | 13 | 0.020 |
Why?
|
| Porosity | 1 | 2012 | 24 | 0.020 |
Why?
|
| DNA Mutational Analysis | 1 | 2011 | 34 | 0.020 |
Why?
|
| Adolescent | 4 | 2001 | 2985 | 0.020 |
Why?
|
| Absorbable Implants | 1 | 2010 | 8 | 0.020 |
Why?
|
| Equipment Design | 1 | 2010 | 27 | 0.020 |
Why?
|
| Gentamicins | 1 | 1990 | 2 | 0.020 |
Why?
|
| Cefazolin | 1 | 1990 | 2 | 0.020 |
Why?
|
| Blood-Retinal Barrier | 1 | 2010 | 2 | 0.020 |
Why?
|
| Blood-Aqueous Barrier | 1 | 2010 | 2 | 0.020 |
Why?
|
| Cyclosporine | 1 | 2010 | 4 | 0.020 |
Why?
|
| Microspheres | 1 | 2010 | 8 | 0.020 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2010 | 34 | 0.020 |
Why?
|
| Surface Properties | 1 | 2010 | 46 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 77 | 0.020 |
Why?
|
| Insulin | 1 | 2010 | 73 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 1990 | 279 | 0.020 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 1990 | 244 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2007 | 13 | 0.020 |
Why?
|
| Technology, Pharmaceutical | 1 | 2007 | 35 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2007 | 76 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2007 | 55 | 0.020 |
Why?
|
| Eye Foreign Bodies | 1 | 1987 | 1 | 0.020 |
Why?
|
| Corneal Injuries | 1 | 1987 | 1 | 0.020 |
Why?
|
| Nutrition Disorders | 1 | 1987 | 3 | 0.020 |
Why?
|
| Research Design | 1 | 2007 | 124 | 0.020 |
Why?
|
| Hardness | 1 | 2006 | 7 | 0.020 |
Why?
|
| Measles | 1 | 1982 | 36 | 0.010 |
Why?
|
| Cholera | 1 | 1981 | 2 | 0.010 |
Why?
|
| Pruritus | 1 | 2001 | 2 | 0.010 |
Why?
|
| Drug Administration Schedule | 1 | 2001 | 156 | 0.010 |
Why?
|
| Immunization | 1 | 1981 | 63 | 0.010 |
Why?
|
| Disease Outbreaks | 1 | 1981 | 111 | 0.010 |
Why?
|
| Double-Blind Method | 1 | 2001 | 272 | 0.010 |
Why?
|
| Infant | 2 | 1982 | 2244 | 0.010 |
Why?
|
| India | 1 | 1982 | 62 | 0.000 |
Why?
|
| Fresh Water | 1 | 1981 | 1 | 0.000 |
Why?
|
| Life Style | 1 | 1981 | 86 | 0.000 |
Why?
|
| Age Factors | 1 | 1982 | 370 | 0.000 |
Why?
|
| Developing Countries | 1 | 1982 | 400 | 0.000 |
Why?
|